Iodoacetamide Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 490

Clinical Trials

Several clinical trials—encompassing Phase 1 and non-applicable phase designs—are currently not yet recruiting to evaluate interventions across chronic obstructive pulmonary disease, ovarian and lung cancers, attention deficit hyperactivity disorder, and sleep disturbances. Supported by academic, foundation, government, and industry sponsors such as the University of Pittsburgh, The Klingenstein Third Generation Foundation, the VA Office of Research and Development, and Novartis Pharmaceuticals, these studies address diverse areas including virtual care delivery, radiopharmaceutical safety, and sensory impacts on sleep.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05986214	Not yet recruiting	Chronic Obstructive Pulmonary Disease	VA Office of Research and Development	2026-03-01	Not Applicable
NCT06376253	Not yet recruiting	Ovarian Cancer\|Lung Cancer	Novartis Pharmaceuticals\|Novartis	2024-09-06	Phase 1
NCT06406309	Not yet recruiting	Attention Deficit Hyperactivity Disorder\|Sleep Disturbance	University of Pittsburgh\|The Klingenstein Third Generation Foundation	2024-09	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Iodoacetamide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Iodoacetamide acts as an alkylating agent that covalently binds to the sulfhydryl groups of reactive cysteine residues, thereby blocking downstream enzyme activity and essential cellular biochemical pathways. This irreversible thiol modification leads to widespread protein dysfunction and cellular toxicity, which underpins its potential biological relevance in oncology applications such as lung and ovarian cancers as well as respiratory conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).